Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 81 of 2034 for:    doxil

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer (Opti-HER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01669239
Recruitment Status : Completed
First Posted : August 20, 2012
Last Update Posted : November 6, 2017
Sponsor:
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016
Publications:
Gavilá J, Llombart A, Guerrero A, Ruíz A, Climent M, Guillem V. Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancer. Poster session presented at: 35th Annual San Antonio Breast Cancer Symposium (SABCS); 2012 December 4th-8th; San Antonio, Texas, United States.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):